Dipatimenti Yapadziko Lonse

Pa Januwale 22, 2025, "Nature Medicine" idasindikiza zotsatira za Akeso payokha idapanga antibody ya PD-1/CTLA-4 bispecific cadonilimab pamodzi ndi oxaliplatin ndi capecitabine kuti igwiritsidwe ntchito pochiza matenda osachiritsika a m'mimba kapena m'mimba omwe ali ndi kachilombo komweko...Werengani zambiri»

Pa Januwale 8, 2025, bungwe la National Medical Products Administration (NMPA) la ku China lavomereza PADCEVTM (enfortumab vedotin) pamodzi ndi KEYTRUDA (pembrolizumab) kwa odwala akuluakulu omwe ali ndi khansa ya urothelial yomwe yakula kwambiri m'deralo (la/mUC). NMPA yavomereza kugwiritsa ntchito enfortumab vedotin mu chisa...Werengani zambiri»

Pa February 17, 2025, Innovent Biologics idalengeza kuti puloteni yake yoyamba ya PD-1/IL-2α-bias bispecific antibody fusion, IBI363, yalandira Fast Track Designation yake yachiwiri (FTD) kuchokera ku US Food and Drug Administration (FDA). Izi zikugwira ntchito pochiza matenda osachiritsika, ...Werengani zambiri»

Pa Januwale 16, 2025, IMPACT yalengeza kuti Senaparib Capsules (派舒宁®）yalandira chilolezo chotsatsa ku China kuchokera ku National Medical Products Administration (NMPA) ngati chithandizo chokhacho chochiritsira odwala akuluakulu omwe ali ndi epithelial yapamwamba (FIGO Stages III ndi IV) yapamwamba kwambiri...Werengani zambiri»

Pa February 7, 2025, Sichuan Kelun-Biotech Biopharmaceutical idalengeza kuvomereza kwa Cetuximab N01 Injection yake ndi National Medical Products Administration pochiza khansa ya m'matumbo yofalikira (mCRC) ku China. Kuvomerezaku kumachokera ku kafukufuku wachipatala waukulu wa gawo lachitatu...Werengani zambiri»

Pa February 10, 2025, CARsgen Therapeutics yalengeza kuti munthu woyamba kulandira chithandizo cha BCMA CAR-T chopangidwa pa nsanja ya THANK-u Plus™, wapeza yankho lokwanira (sCR) komanso matenda ochepa otsalira (MRD) pakuwunika kwa Tsiku la 28. Yapangidwa m'nyumba...Werengani zambiri»

Pa Januwale 29, 2025, gulu lofufuza la ku China linasindikiza nkhani yotchedwa "Neoadjuvant pyrotinib ndi trastuzumab mu khansa ya m'mawere ya HER2 yomwe ili ndi kachilombo popanda kuyankha koyambirira (NeoPaTHer): kugwira ntchito bwino, chitetezo, ndi kusanthula kwa biomarker kwa kafukufuku woyembekezeredwa, wokhudzana ndi mayankho ambiri" mu ...Werengani zambiri»

Pa Januwale 26, 2025, Center for Drug Evaluation (CDE) ya China National Medical Products Administration idalengeza kuti jakisoni wa LM-108 cholinga chake ndikuphatikizidwa mu chithandizo chamankhwala cha zotupa zolimba zomwe zili ndi kusakhazikika kwa microsatellite (MSI-H) kapena zolakwika zokonzanso zolakwika (dMMR) zomwe...Werengani zambiri»

Pa Januware 20, National Medical Products Administration (NMPA) yavomereza mankhwala atsopano a monoclonal antibody tagitanlimab (omwe kale anali KL-A167) ophatikizana a cisplatin ndi gemcitabine kuti agwiritsidwe ntchito pochiza odwala omwe amabwereranso kapena kufalikira kwa khansa ya m'mphuno (NPC). ...Werengani zambiri»

Pa Januwale 16, 2025, bungwe la National Medical Products Administration (NMPA) la ku China lavomereza kugwiritsa ntchito mankhwala atsopano a limertinib (NDA) pochiza odwala akuluakulu omwe ali ndi khansa ya m'mapapo ya EGFR T790M yomwe si yaing'ono (NSCLC) yomwe yakula kwambiri kapena yofalikira m'derali. Zokhudza Limertinib Limertinib ...Werengani zambiri»

Pa Januwale 8, Center for Drug Evaluation (CDE) ya China's National Medical Products Administration (NMPA) yapereka Breakthrough Therapy Designation (BTD) ya IBI343, mankhwala abwino kwambiri oletsa CLDN18.2 ADC, ngati mankhwala amodzi ochizira matenda a CLDN18.2-positive advanced pancr...Werengani zambiri»

Pa Januwale 8, 2025, 9MW2821 idapatsidwa Breakthrough Therapy Designation (BTD) ndi Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) ku China. 9MW2821 idaperekedwa pamodzi ndi toripalimab, antibody yotsutsana ndi PD-1 monoclonal, kuti igwiritsidwe ntchito pochiza matenda osachiritsika, osachiritsika...Werengani zambiri»